| Metric | Value (₹ Cr) | vs Q2 FY25 |
|---|---|---|
| Revenue | 93.86 | 4.8% |
| Total Income | 95.77 | 4.8% |
| Expenditure | 120.92 | 13.1% |
| PBT | -25.15 | 34.8% |
| Net Profit | -40.37 | 4.7% |
| OPM | -51.55% | 10.70pp |
| NPM | -42.15% | 3.81pp |
| EPS | -20.59 | 4.7% |
Astec LifeSciences Reports 85% Increase in Q3 FY25 Total Income and 78% Narrower EBITDA Loss
28 Jan 2025 · 28 Jan 2025, 12:11 am
Summary
Astec LifeSciences Limited has announced its financial results for the third quarter ended December 31, 2024. The company's consolidated total income stood at ₹ 95.8 Crore in Q3 FY25, a 85% increase from ₹ 51.7 Crore in Q3 FY24. The consolidated EBITDA loss narrowed down to ₹ 3.8 Crore in Q3 FY25 from a loss of ₹ 17.4 Crore in Q3 FY24. For 9M FY25, the company reported a consolidated total income of ₹ 266.6 Crore and a consolidated EBITDA loss of ₹ 66.9 Crore.
Key Highlights
- 1
Q3 FY25 consolidated total income increased by 85% YoY to ₹ 95.8 Crore
- 2
Q3 FY25 consolidated EBITDA loss narrowed down by 78% YoY to ₹ 3.8 Crore
- 3
9M FY25 consolidated total income stood at ₹ 266.6 Crore
- 4
9M FY25 consolidated EBITDA loss was ₹ 66.9 Crore
- 5
Sequential improvement in performance with narrowing EBITDA losses in Q3 FY25
Management Comments
Mr. N B Godrej
Chairman, Astec LifeSciences Limited
In Q3 FY25, Astec reported sequential improvement in performance, narrowing EBITDA losses from ₹ 17.7 Crore in Q2 FY25 to ₹ 3.8 Crore in Q3 FY25. This positive trend was primarily due to a sequential increase in volumes in our Contract Development and Manufacturing Organization (CDMO) business. However, this positive impact was offset by continued lower realizations in key Enterprise products. We anticipate gradual performance enhancement in the coming quarters.
Informational and educational content only. Not investment advice.